1. Accompanying diseases other than COVID-19 with an expected survival time of less than 12 months 2. In the opinion of the clinical team, progression to death is imminent and inevitable with-in the next 24 hours, irrespective of the provision of treatment 3. Chronic obstructive lung disease (COPD), stage 4 4. Lung fibrosis with UIP pattern in CT und severe emphysema 5. Chronic heart failure NYHA >= 3 and/or pre-existing reduction of left ventricular ejection fraction to ≤ 30% 6. Liver cirrhosis Child C 7. Liver failure: Bilirubin > 5xULN and elevation of ALT /AST (at least one >10xULN). 8. End stage renal failure requiring hemodialysis 9. Organ or bone marrow transplant in the three month prior to screening 10. History of adverse reactions to plasma proteins 11. Known deficiency of immunoglobulin A 12. Pregnancy and breastfeeding women 13. Volume overload until sufficiently treated 14. Pulmonary edema 15. Body mass index (BMI) > 40 kg/m2 16. Participation in another clinical trial, especially for treatment of COVID-19 17. Allergy or other contraindication to one of the investigational products 18. Previous treatment with SARS-CoV-2 convalescent plasma

1. Accompanying diseases other than COVID-19 with an expected survival time of less than 12 months 2. In the opinion of the clinical team, progression to death is imminent and inevitable with-in the next 24 hours, irrespective of the provision of treatment 3. Chronic obstructive lung disease (COPD), stage 4 4. Lung fibrosis with UIP pattern in CT und severe emphysema 5. Chronic heart failure NYHA >= 3 and/or pre-existing reduction of left ventricular ejection fraction to ≤ 30% 6. Liver cirrhosis Child C 7. Liver failure: Bilirubin > 5xULN and elevation of ALT /AST (at least one >10xULN). 8. End stage renal failure requiring hemodialysis 9. Organ or bone marrow transplant in the three month prior to screening 10. History of adverse reactions to plasma proteins 11. Known deficiency of immunoglobulin A 12. Pregnancy and breastfeeding women 13. Volume overload until sufficiently treated 14. Pulmonary edema 15. Body mass index (BMI) > 40 kg/m2 16. Participation in another clinical trial, especially for treatment of COVID-19 17. Allergy or other contraindication to one of the investigational products 18. Previous treatment with SARS-CoV-2 convalescent plasma

1. Accompanying diseases other than COVID-19 with an expected survival time of less than 12 months 2. In the opinion of the clinical team, progression to death is imminent and inevitable with-in the next 24 hours, irrespective of the provision of treatment 3. Chronic obstructive lung disease (COPD), stage 4 4. Lung fibrosis with UIP pattern in CT und severe emphysema 5. Chronic heart failure NYHA >= 3 and/or pre-existing reduction of left ventricular ejection fraction to ≤ 30% 6. Liver cirrhosis Child C 7. Liver failure: Bilirubin > 5xULN and elevation of ALT /AST (at least one >10xULN). 8. End stage renal failure requiring hemodialysis 9. Organ or bone marrow transplant in the three month prior to screening 10. History of adverse reactions to plasma proteins 11. Known deficiency of immunoglobulin A 12. Pregnancy and breastfeeding women 13. Volume overload until sufficiently treated 14. Pulmonary edema 15. Body mass index (BMI) ≥ 30 kg/m2 16. Participation in another clinical trial, especially for treatment of COVID-19 17. Allergy or other contraindication to one of the investigational products 18. Previous treatment with SARS-CoV-2 convalescent plasma

1. Accompanying diseases other than COVID-19 with an expected survival time of less than 12 months 2. In the opinion of the clinical team, progression to death is imminent and inevitable with-in the next 24 hours, irrespective of the provision of treatment 3. Chronic obstructive lung disease (COPD), stage 4 4. Lung fibrosis with UIP pattern in CT und severe emphysema 5. Chronic heart failure NYHA >= 3 and/or pre-existing reduction of left ventricular ejection fraction to ≤ 30% 6. Liver cirrhosis Child C 7. Liver failure: Bilirubin > 5xULN and elevation of ALT /AST (at least one >10xULN). 8. End stage renal failure requiring hemodialysis 9. Organ or bone marrow transplant in the three month prior to screening 10. History of adverse reactions to plasma proteins 11. Known deficiency of immunoglobulin A 12. Pregnancy and breastfeeding women 13. Volume overload until sufficiently treated 14. Pulmonary edema 15. Body mass index (BMI) ≥ 30 kg/m2 16. Participation in another clinical trial, especially for treatment of COVID-19 17. Allergy or other contraindication to one of the investigational products 18. Previous treatment with SARS-CoV-2 convalescent plasma